Pneumoconiosis Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial of Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis
This study is a randomized, double-blind, placebo-controlled, multicenter clinical study. The main purpose of this study was to confirm the efficacy and safety of pirfenidone capsules in the treatment of pneumoconiosis.
272 patients with pneumoconiosis participated in the 52-week study and were randomized to pirfenidone or placebo. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04022902 -
The Experience of Patients and Family Caregivers in Managing Pneumoconiosis in the Family Context
|
||
| Recruiting |
NCT05365802 -
FAPI PET for Lung Fibrosis
|
Early Phase 1 | |
| Completed |
NCT00005280 -
Specialized Center of Research in Occupational and Immunologic Lung Disease
|
N/A | |
| Completed |
NCT02668068 -
A Study on Pneumoconiosis Treated With Whole-lung Lavage Combined With Mesenchymal Stem Cells
|
Phase 1 | |
| Completed |
NCT04963348 -
Potential of Deep Learning in Assessing Pneumoconiosis Depicted on Digital Chest Radiography
|
||
| Recruiting |
NCT04952675 -
Evaluation of Pneumoconiosis High Risk Early Warning Models
|